BriaCell Therapeutics Corp Ordinary Shares - New BCTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
-
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
-
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
-
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
-
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
-
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
Trading Information
- Previous Close Price
- $3.50
- Day Range
- $3.42–3.67
- 52-Week Range
- $2.60–13.43
- Bid/Ask
- $3.42 / $3.54
- Shares Outstanding
- 8.73M
- Market Cap
- $30.54M
- Volume/Avg
- 32,221 / 259,673
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
BriaCell Therapeutics Corp is a clinical-stage biotechnology company developing targeted immunotherapies to transform cancer care. Its Bria-IMT targeted immunotherapy is being developed in combination with the immune checkpoint inhibitor Retifanlimab in a pivotal Phase 3 study in metastatic breast cancer. The Company's operations focus on the research and development of its immunotherapy product candidates and related supporting activities.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 31
- Website
- https://www.briacell.com
Valuation
|
Metric
|
BCTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
BCTX
Financial Strength
|
Metric
|
BCTX
|
|---|---|
Quick Ratio | 2.66 |
Current Ratio | 2.76 |
Interest Coverage | −1,212.56 |
Quick Ratio
BCTX
Profitability
|
Metric
|
BCTX
|
|---|---|
Return on Assets (Normalized) | −142.87% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −179.62% |
Return on Assets
BCTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|p?Rv@>? | LOCK|dC#W@ | $134B | |||
| Moderna Inc
MRNA
| LOCK|#j<?lX | LOCK|dyR | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|LbY<Bf> | LOCK|t?%^% | $84B | |||
| argenx SE ADR
ARGX
| LOCK|f%!Q#! | LOCK|@fY | $56B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|HKX%$C | LOCK|$< | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|c^^%zKH | LOCK|&$Fb | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|F>&V!J^? | LOCK|>^hw | $29B | |||
| Incyte Corp
INCY
| LOCK|Yb%%^H | LOCK|pS | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|#R%@%!T | LOCK|$$ | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|V@wdm@F | LOCK|GQ< | $14B |
United States